Chemomab Therapeutics (CMMB) Tops Q4 EPS by 3c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q4 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Ameramex International, Inc. (AMMX) Reports In-Line Q2 EPS
• Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update